Modeling how antibodies protect against influenza
Multiscale Modeling of Influenza Neutralizing Antibody and Fc Effector Biology
['FUNDING_U01'] · DUKE UNIVERSITY · NIH-11016775
This study is looking at how our body's antibodies fight off the flu, so researchers can create better vaccines that work well for everyone, helping to keep you safe from seasonal and pandemic flu strains.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-11016775 on ClinicalTrials.gov |
What this research studies
This research aims to develop advanced computational models to predict how antibodies respond to influenza viruses. By analyzing extensive data from infections and vaccinations, the team will create simulations that help understand how a diverse mix of antibodies can provide better protection against the flu. The goal is to improve vaccine effectiveness by identifying the best antibody responses needed to combat seasonal and pandemic influenza strains. Patients may benefit from insights that lead to more effective vaccines tailored to their immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are at high risk for influenza, such as the elderly, immunocompromised patients, and those with chronic health conditions.
Not a fit: Patients who are not at risk for influenza or those who have already received effective vaccination may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective influenza vaccines that provide better protection against both seasonal and pandemic strains.
How similar studies have performed: Other research has shown promise in using computational models to enhance vaccine development, indicating that this approach could lead to significant advancements in flu prevention.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHAN, CLIBURN C — DUKE UNIVERSITY
- Study coordinator: CHAN, CLIBURN C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.